CJC-1295 (No DAC), Hexarelin Blend is a lyophilized peptide mixture supplied exclusively for controlled laboratory research. It contains CJC-1295 without Drug Affinity Complex and Hexarelin for analytical studies involving growth hormone–releasing hormone receptor pathways, growth hormone secretagogue receptor pathways, peptide identity, receptor-binding behavior, and GH-axis research models.
This material is intended only for in-vitro laboratory testing, analytical evaluation, and controlled scientific experimentation by qualified personnel.
For laboratory research use only. Not for human or animal consumption. Not intended for in-vivo, diagnostic, therapeutic, food, cosmetic, or supplement use.
CJC-1295 (No DAC), Hexarelin Blend Specifications:
| Specification | Information |
|---|---|
| Product identity | CJC-1295 (No DAC) and Hexarelin peptide blend |
| Component classification | Modified GHRH analog and growth hormone secretagogue |
| Form | Lyophilized powder |
| Appearance | Dry peptide material |
| Purity and identity | Refer to the batch-specific Certificate of Analysis |
| Analytical documentation | Lot-specific testing documentation available |
| Testing methods | Refer to the applicable COA for reported analytical methods and results |
| Storage | Store sealed in a cool, dry environment away from heat, direct light, and moisture |
| Intended setting | Controlled laboratory research |
| Restrictions | Not for human, animal, veterinary, diagnostic, therapeutic, food, cosmetic, or supplement use |
NordSci uses independent analytical testing and makes batch-specific Certificates of Analysis available for product verification and laboratory recordkeeping.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
CJC-1295 (No DAC), Hexarelin Blend is a lyophilized peptide mixture supplied exclusively for controlled laboratory research. It contains CJC-1295 without Drug Affinity Complex and Hexarelin for analytical studies involving growth hormone-releasing hormone receptor pathways, growth hormone secretagogue receptor pathways, peptide identity, receptor-binding behavior, and GH-axis research models.
This material is intended only for in-vitro laboratory testing, analytical evaluation, and controlled scientific experimentation by qualified personnel. Research involving this blend should use predetermined endpoints, appropriate controls, standardized laboratory conditions, and complete experimental documentation.
For laboratory research use only. Not for human or animal consumption. Not intended for in-vivo, diagnostic, therapeutic, food, cosmetic, supplement, or veterinary use.
CJC-1295 (No DAC), Hexarelin Blend – Research Specifications:
| Product Identity | CJC-1295 (No DAC) and Hexarelin peptide blend |
| Component Classification | Modified GHRH analog and synthetic growth hormone secretagogue |
| Format | Lyophilized peptide blend |
| Appearance | Dry lyophilized powder |
| Purity and Identity | Refer to the batch-specific Certificate of Analysis for applicable analytical data |
| Analytical Documentation | Lot-specific testing documentation is available through the NordSci COA Library |
| Testing Methods | Refer to the applicable COA for reported analytical methods and results |
| Storage Conditions | Store sealed in a cool, dry environment away from direct light, heat, and moisture. Follow laboratory SOPs and applicable batch documentation. |
| Research Use Only | Supplied exclusively for controlled laboratory research. Not for human, animal, veterinary, diagnostic, therapeutic, food, cosmetic, or supplement use. |
CJC-1295 without DAC is classified as a modified growth hormone-releasing hormone analog. The absence of the Drug Affinity Complex distinguishes this research material from DAC-modified variants and permits comparative laboratory evaluation of different molecular formats.
Hexarelin is a synthetic peptide associated with growth hormone secretagogue receptor research. Laboratory investigations may examine its identity, receptor affinity, binding characteristics, concentration-dependent assay behavior, and interaction with GHS-R1a pathway models.
Combining these compounds provides researchers with a defined blend for examining two receptor-associated mechanisms within the same experimental system. Appropriate studies may compare the blend with individual-component controls to characterize assay behavior, analytical differentiation, and pathway interaction under standardized conditions.
Researchers requiring single-variable controls can reference the individual product pages for CJC-1295 without DAC and Hexarelin.
Important Research Notice: Each product lot is associated with analytical documentation for identity and quality verification. Laboratories should retain the applicable COA with their procurement and experimental records.
THIS PRODUCT IS INTENDED EXCLUSIVELY FOR LABORATORY RESEARCH. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR IN-VIVO, DIAGNOSTIC, THERAPEUTIC, FOOD, COSMETIC, SUPPLEMENT, OR VETERINARY USE.
This blend may be examined in controlled GH-axis research models using defined sampling intervals and laboratory biomarkers. Experimental designs should include appropriate controls, predetermined analytical endpoints, and documented procedures.
Laboratories may use the blend to examine GHRH receptor and GHS-R1a pathway activity within qualified experimental systems. Research can focus on receptor interaction, pathway differentiation, assay sensitivity, and measurable laboratory signals.
The blended material can be compared with CJC-1295 without DAC and Hexarelin as separate controls. This structure permits researchers to distinguish blend-associated assay observations from those recorded for each individual component.
Defined laboratory models may examine measurable markers associated with GH-axis signaling. Findings should remain limited to the analytical endpoints, assay conditions, and methodology established by the research protocol and should not be interpreted as evidence of a human or animal outcome.
Handle this material only in appropriately equipped laboratory facilities using validated procedures for research peptides. Maintain documented chain of custody, contamination controls, lot traceability, calibrated equipment, and clearly defined acceptance criteria.
Protocol Design Considerations: Experimental records should identify the product, lot number, analytical method, control materials, environmental conditions, sampling intervals, and observed results. Conclusions should remain limited to the specific laboratory model and methodology used.
This information is provided exclusively as a laboratory research reference. Experimental work must be conducted by qualified personnel in appropriate research facilities.
A batch-specific Certificate of Analysis is available for this peptide blend. The COA provides analytical information associated with the applicable lot and may include identity, purity, testing methods, and related quality-control data.
Researchers should confirm that the product name and lot number on the vial correspond with the applicable COA before incorporating the material into a laboratory workflow.
Laboratories sourcing CJC-1295 (No DAC), Hexarelin Blend should prioritize lot traceability, defined research restrictions, documented quality-control procedures, and batch-specific analytical records.
NordSci Peptides supplies this blend as a laboratory research material with independent analytical testing and access to applicable COA documentation.
IMPORTANT: This product is supplied exclusively for controlled laboratory research. It is not an FDA-approved drug, dietary supplement, food, or cosmetic. It is not intended for human or animal consumption or for in-vivo, diagnostic, therapeutic, veterinary, or other consumer use.
